Wegovy Pill Sales Hit $810M as Novo Nordisk Raises 2026 Outlook
Novo Nordisk raised its 2026 outlook after third-quarter Wegovy pill sales of about $810M beat forecasts, helped by Medicare's $50 copay and lower drug prices.
The cost of prescription medications sits at the intersection of public health, corporate strategy, and government policy, making it one of the most closely watched issues in American healthcare. For decades, patients, insurers, and lawmakers have grappled with why the same drugs often cost far more in the United States than in other countries, and why prices for life-saving treatments can rise sharply even as competitors enter the market.
This topic matters now more than ever as policymakers test new tools to rein in costs. Medicare's negotiation authority, established under recent federal law, has begun reshaping the relationship between government payers and pharmaceutical manufacturers, prompting both compliance and legal pushback from drugmakers who argue the process undermines innovation incentives. At the same time, new therapies—including advanced treatments for cancers and rare diseases—continue to enter the pipeline, raising fresh questions about how breakthrough science and affordability can coexist.
Readers will find ongoing coverage of the legal and legislative battles over drug pricing reform, including lawsuits challenging Medicare's negotiated rates and state-level efforts to cap costs. This hub also tracks the business side of the industry: how manufacturers respond to pricing pressure, shifts in list prices versus net prices after rebates, and the competitive dynamics introduced by generics and biosimilars. Coverage extends to the human impact—patient access issues, insurance coverage disputes, and the affordability challenges facing people managing chronic conditions.
As new drugs reach approval and pricing policies evolve, this page will serve as a continually updated resource for understanding how affordability, innovation, and regulation intersect in the pharmaceutical marketplace.
Novo Nordisk raised its 2026 outlook after third-quarter Wegovy pill sales of about $810M beat forecasts, helped by Medicare's $50 copay and lower drug prices.
KFF projects stand-alone Medicare Part D premiums will rise 50%, from $34 to $51 a month in 2027, for seniors who keep their plans. CMS projects about $1.
KFF projects stand-alone Medicare Part D premiums will rise 50% to $51 a month in 2027 for enrollees who don't switch, far above CMS's $1 estimate.
Stand-alone Medicare drug plan premiums will rise about 50% in 2027, KFF finds, after CMS ended a subsidy early, even as Trump touts lower drug prices.
In a Phase 3 head-to-head trial, Lilly's retatrutide cut weight 19.5-20.9% vs Ozempic's 9.4%. Lilly plans to file with the FDA in 2027 as obesity drug sales
KFF finds stand-alone Medicare drug plan premiums will average 50% higher in 2027, even as Trump claims the world's lowest drug prices before the midterms.
UnitedHealth, Humana and others are dropping Medicare Advantage plans for 2027, forcing 1M to 3.8M seniors to switch as costs rise across U.S. health care.
KFF projects average Medicare stand-alone drug plan premiums will rise 50% to $51 in 2027 for enrollees who don't switch, as Trump touts drug pricing wins.
Eli Lilly raised its 2026 revenue forecast to $91-92 billion after Q3 sales jumped 39% to $24.4 billion on Mounjaro and Zepbound, despite lower drug prices.
Eli Lilly shares hit a record $1,408 after Q3 revenue rose 39% to $24.4B and it raised its 2026 forecast to $91–92B on Mounjaro and Zepbound demand.
Insurers including UnitedHealth and Humana are dropping Medicare Advantage plans for 2027, leaving millions to switch and nearly 200 counties with no options.
Medicare's negotiated prices for 15 more drugs, including Ozempic and Wegovy, start Jan. 1, 2027, with cuts of 38% to 85%, while deductibles and employer costs
Hospital-owned doctors' offices bill routine care at hospital rates plus facility fees, inflating some bills tenfold as regulators and states push back.
KFF's 2026 survey finds family premiums averaged $28,303, up 5%. Workers' share jumped 9% to $7,471, and 8% to 11% cost increases are forecast for 2027.
Humana and UnitedHealthcare are ending Medicare Advantage plans for about 990,000 seniors in 2027, citing rising costs. Open enrollment ends December 7.
Humana and UnitedHealthcare are ending Medicare Advantage plans for about 990,000 seniors in 2027 as drug, employer and hospital costs keep rising.
KFF says family job-based coverage costs $28,303 in 2026, up 5%, while workers' share rose 9% to $7,471 as Medicaid cuts and 2027 increases loom.
Employer health costs are projected to rise 8% to 11% in 2027, the most in 20 years, as Medicaid work rules and new Medicare drug prices begin Jan. 1.
UnitedHealthcare and Humana are ending Medicare Advantage plans for about 990,000 people in 2027 as Part D, employer and Medicaid costs also shift to patients.
Medicare's negotiated prices for 15 Part D drugs, including Ozempic at $274, take effect Jan. 1, 2027. What patients pay still depends on their plan.
Blue Cross, Medica, HealthPartners, UnitedHealthcare and Humana are dropping 2027 Medicare Advantage plans, sending 320,000+ Minnesotans to shop.
An EMA committee recommended EU approval of Eli Lilly's Foundayo pill for obesity and type 2 diabetes, putting it up against Novo's Wegovy pill.
An AARP study finds Medicare could save $197B on 10 top drugs from 2029-2033 by paying international prices. Congress would have to approve the change.
Insurers are ending Medicare Advantage plans for 2027, forcing over 3 million enrollees to choose new coverage as open enrollment begins Oct. 15.
Stelara's $4,695 Medicare negotiated price cuts 66% off list, yet biosimilars discounted 75–90% already undercut it as CMS proposes permanent rules.
CMS set a $274 negotiated Medicare price for Ozempic, Wegovy and Rybelsus for 2027, but a $245 most-favored-nation deal is expected to take precedence.
U.S. prescription drug prices fell 3.1% in the year to July, the most since 1963. Trump claims credit; experts cite Medicare negotiation and competition.
Medicare open enrollment began Oct. 15 with fewer Advantage plans, over 3 million enrollees forced to switch, and higher Part D deductibles and caps.
About 3.2 million Medicare Advantage enrollees must pick new plans for 2027 as insurers cut plans and raise out-of-pocket caps and drug deductibles.
Novo Nordisk will cut Ozempic, Wegovy and Rybelsus list prices to $675 a month in 2027, alongside separate $274 and $245 Medicare prices.